NCT06693024View on ClinicalTrials.gov

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

2,806

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

neratinib

neratinib 240mg qd for 1 year

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER